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Abstract 
 
Breast cancer is the most common solid tumor and the second most common cause of death in 
women. Despite a large body of literature and progress in breast cancer research, many 
molecular aspects of this complex disease are still poorly understood, hindering the design of 
specific and effective therapeutic strategies. To identify molecules important in breast cancer 
progression and metastasis, we tested the in vivo effects of inhibiting the functions of various 
kinases and genes involved in the regulation/modulation of the cytoskeleton by downregulating 
them in mouse PyMT mammary tumor cells and human breast cancer cell lines. These kinases 
and cytoskeletal regulators were selected based on their prognostic values for breast cancer 
patient survival. PyMT tumor cells in which a selected gene was stably knocked down were 
injected into the tail veins of mice and the formation of tumors in the lungs was monitored. One 
of several genes found to be important for tumor growth in lungs was Nek2, a cell cycle-related 
protein kinase. Furthermore, Nek2 was also important for tumor growth in the mammary fat pad. 
In various human breast cancer cell lines, Nek2 knockdown induced aneuploidy and cell cycle 
arrest that led to cell death. Significantly, the breast cancer cell line most sensitive to Nek2 
depletion was of the triple negative breast cancer subtype. Our data indicate that Nek2 plays a 
pivotal role in breast cancer growth at primary and secondary sites, and thus may be an attractive 
and novel therapeutic target for this disease. 
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Introduction 
 
Breast cancer is the most common female malignancy in North America and the second most 
common cause of cancer death in women (1). Breast tumors are classified into specific subtypes 
based on cellular morphology and the presence/absence of the estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor-2 (ERBB2/HER2). 
Examinations of each subtype’s pathophysiology have generated targeted therapies that have 
extended the survival of some patients with metastatic breast cancers. Such therapies, which 
include taxanes, aromatase inhibitors, and trastuzumab (2, 3), have significantly improved 
outcomes for patients with breast cancers of the luminal or HER2 subtypes. Sadly, an effective 
targeted treatment is still lacking for patients whose tumors are of the highly aggressive triple 
negative breast cancer (TNBC) subtype (4, 5). 
   Because kinases are crucial for cancer cell survival, mitosis, migration and invasion, much 
research has been focused on developing inhibitors against them (6-8). Rapidly proliferating 
tumors like TNBCs rely on tight temporal regulation of the cell cycle and centrosome 
duplication. Inhibition of kinases associated with mitosis induces severe defects in centrosome 
duplication and chromosome segregation that ultimately lead to aneuploidy and cell death (9-12). 
The future of TNBC management may therefore lie in the identification of new cell cycle 
regulators that control breast cancer progression and metastasis. 
   The Nek proteins belong to a family of serine/threonine kinases named after the NIMA gene 
originally cloned in Aspergillus nidulans (14). In mammals, there are 11 family members (Nek1-
Nek11) but only four of these proteins, Nek2, Nek6, Nek7 and Nek9, play roles in mitotic 
progression (15). Of particular interest is Nek2, which localizes to the centrosome/centriole and 
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helps to establish a bipolar spindle by initiating the separation of centrosomes (16-18). High 
levels of NEK2 protein have been previously described in breast cancers (19), and Nek2 mRNA 
overexpression has been reported in different breast cancer subtypes (20, 21). These 
observations, coupled with Nek2’s function as a major centrosome regulator, marks this kinase 
as an emerging target of drug discovery interest (43-45). 
   In this study, we show that cancer cells lacking Nek2 exhibit aberrant mitosis leading to 
apoptosis. Furthermore, Nek2 knockdown in cancer cells induces aneuploidy, cell cycle arrest, 
and caspase-dependent and -independent cell death. Mechanistically, Nek2 depletion promotes 
the activity of the tumor suppressor pRb while simultaneously reducing the activation of the cell 
division regulator histone H3. In vivo, mouse and human cancer cells lacking Nek2 expression 
grow more slowly than control cells and give rise to reduced tumor burden in the lungs. Our 
results suggest that Nek2 inhibition could help to disrupt the cell cycle of TNBC cells, enhancing 
the effects of current chemotherapeutic interventions. 
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Results 
 
High Nek2 expression correlates with poor prognosis in breast cancer patients 
To identify specific kinases and cytoskeletal regulators important for breast cancer cell survival 
in vivo, we used stable expression of short-hairpin RNA (shRNA) to silence genes encoding 
selected cytoskeletal regulators and kinases in mouse PyMT mammary tumors [PyMT cells, 
previously described in (13)]. We selected candidates whose high expression correlated 
positively with greater risk of patient mortality as evaluated in a cohort of 2312 breast cancer 
patients (Figure 1a). By choosing a cut-off of 1.2 for the hazard ratio (HR), we compiled a list of 
14 target genes suitable for further study in vivo. We silenced each gene individually in PyMT 
cells (Supplementary Figure S1a) and intravenously (IV) injected the modified cells into 
syngeneic recipient mice. The recipients have been monitored to assess if the lack of each target 
gene is able to suppress tumor growth in the lung (Supplementary Figure S1b). Based on our in 
vivo results and the pharmacological tractability of our 14 genes (as determined by consulting 
sources such as ChEmbl, PubChem, Drugbank and Sophic Druggable Genome), we chose Nek2 
for further in-depth investigation. We first confirmed that Nek2 mRNA is overexpressed in 
basal-like as well as non-basal-like breast cancers in comparison to normal breast tissue (Figure 
1b), and showed that Nek2 overexpression correlates positively with a greater risk of patient 
mortality (Figure 1c). We also demonstrated that Nek2 overexpression correlates positively with 
disease recurrence (Figure 1d) (22) in breast cancer patients. In order to correlate NEK2 protein 
expression between normal and malignant breast tissue we performed immunohistological 
analysis on a tissue microarray (TMA) comprised of TNBC samples from a cohort of 39 patients 
(Supplementary Table S1). Invasive ductal carcinomas (IDCs) showed a markedly increased 
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number of cells expressing nuclear NEK2 in comparison to normal breast tissue (Figure 1e, f). 
Notably, about 45% of all normal breast tissue showed zero nuclear NEK2 expression intensity 
whereas only about 5% of IDCs were considered to have no expression. Conversely, about 36% 
of all IDCs showed strong nuclear NEK2 expression in comparison to about 3% of normal breast 
tissue samples (Figure 1g). These results affirm the relevance of evaluating Nek2 as a potential 
target in human breast cancer. 
 
Nek2 promotes the growth of PyMT cells in the lung 
To study the role of Nek2 in tumor growth, we stably knocked down Nek2 in luciferase-
expressing PyMT cells using specific shRNA (PyMT-shNek2) (Figure 2a, b). We then injected 
PyMT-shNek2 or PyMT-ctr cells (expressing scramble shRNA) into female syngeneic mice via 
the tail vein and performed live animal imaging to monitor tumor growth in the lungs. At 4 
weeks post-injection, tumor cell engraftment was readily detected in all mice injected with 
PyMT-ctr cells but rarely in mice injected with PyMT-shNek2 cells (Figure 2c). Moreover, while 
all control mice died by 20 weeks post-injection, 50% of mice injected with PyMT-shNek2 cells 
survived past that timepoint, and 20% of these mice were still alive at 50 weeks post-injection 
(Figure 2d). 
   Because of Nek2’s known role in mitotic progression (18), we analyzed the cell cycle in 
PyMT-shNek2 and control cells after serum starvation or nocodazole treatment. Nek2 
knockdown increased the G1 population and modestly enhanced the G2/M population, indicating 
that cell cycle arrest had occurred (Figure 2e, f). However, the most interesting effect of Nek2 
silencing was the eventual generation of an aneuploid cell population. This aneuploid subset 
comprised 64% of all PyMT-shNek2 cells at 48 hrs after serum replenishment but was virtually 
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absent (0.3% at 48 hrs) in control cells (Figure 2e, g). A similar trend was observed following 
release from nocodazole treatment (Supplementary Figure S2). We hypothesized that this 
induction of aneuploidy upon Nek2 knockdown could underlie the observed increase in G1 cells, 
and might explain the significant reduction in tumor growth in mice bearing PyMT-shNek2 cells. 
 
Nek2 promotes the growth of human breast cancer cells in vivo 
To determine whether Nek2 is also important for the cell cycle in human breast cancer cells, we 
transduced luciferase-expressing MDA-MB-231 cells (TNBC cell line) with either scramble 
shRNA (MDA-MB-231-ctr) or Nek2 shRNA (MDA-MB-231-shNek2) (Figure 3a, b). A 
previous study showed that the in vivo growth of MCF7 or MDA-MB-231 human breast cancer 
cells could be inhibited by injecting siRNA against Nek2 directly into tumors (23). We injected 
MDA-MB-231-shNek2 or control cells into either the tail veins of NOD-SCID mice, or into the 
fat pads of female NIH-III mice. In NOD-SCID mice, even at 3 weeks post-injection, we 
detected more tumor cells in the lungs of the animals injected with control cells than in the lungs 
of those injected with MDA-MB-231-shNek2 cells (Figure 3c). While all control NOD-SCID 
mice died by 6 weeks post-injection, 20% of NOD-SCID mice injected with MDA-MB-231-
shNek2 cells were still alive at 10 weeks post-injection (Figure 3d). Similarly, MDA-MB-231-
shNek2 cells injected into the fat pads of NIH-III mice generated tumors that were significantly 
smaller than those derived from control cells (Figure 3e). Histological analysis of lungs excised 
from NOD-SCID mice at 5 weeks post-injection confirmed the presence of a significantly 
reduced tumor burden in animals that received MDA-MB-231-shNek2 cells compared to those 
injected with control cells, as indicated by the reduced ratio of tumor area to normal tissue in the 
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former group (Figure 3f). These findings suggest that Nek2 promotes the growth of human breast 
cancer cells in primary and secondary sites. 
 
Nek2 depletion results in cell cycle defects, centrosomal alterations, and aneuploidy in human 
breast cancer cells 
To understand Nek2’s pro-tumorigenic role in human breast cancer cells, we evaluated the cell 
cycle progression of MDA-MB-231-shNek2 cells. We detected a large aneuploid cell population 
that represented 20-30% of all serum-starved cells, and 60-80% of all nocodazole-treated cells 
(Figure 4a, c and Supplementary Figure S3). Compared to cultures of PyMT-shNek2 cells, 
MDA-MB-231-shNek2 cells showed a larger increase in the subG1 population (dead cells; 
Figure 4b). Furthermore, the proliferative capacity of MDA-MB-231-shNek2 cells was reduced 
compared to control cells (Figure 4d), a defect confirmed by the decreased percentage of BrdU+ 
cells detected in MDA-MB-231-shNek2 cultures (Figure 4e, f). This impaired proliferation in the 
absence of Nek2 was also observed in several other human breast cancer cell lines subjected to 
Nek2 knockdown, including HCC1806 cells (TNBC), T47D cells (luminal A breast cancer), and 
MCF7 cells (luminal A breast cancer) (Supplementary Figure S4). Interestingly, the responses of 
different human breast cancer cells to Nek2 knockdown were not uniform. HCC1806-shNek2 
cultures showed an abnormally high percentage of cells in the G2/M and subG1 phases but no 
aneuploidy (Supplementary Figure S5). In contrast, both an aneuploid cell population and an 
expanded subG1 population were detected in T47D-shNek2 cells (Supplementary Figure S6). 
MCF7-shNek2 cells displayed a decreased proliferation rate compared to controls, in line with 
their slight increase in G2/M phase (Supplementary Figure S7). These results emphasize the 
heterogeneity of human breast cancers but also suggest that inhibition of Nek2 can interfere with 
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the growth of different breast cancer subtypes. The reduced tumor burden observed in the lungs 
of mice injected with MDA-MB-231-shNek2 cells (refer to Figure 3f) could also result from 
defects in cell migration or invasion. We therefore evaluated these capacities in MDA-MB-231-
shNek2 cells using real-time and transwell migration and invasion assays. MDA-MB-231-
shNek2 cells showed slightly decreased migration ability compared to control cells but no 
difference in invasion capacity (Supplementary Figure S8). These data imply that the reduced 
growth of Nek2-depleted cells in lungs is mainly due to cell cycle abnormalities, aneuploidy, and 
cell death, with little or no contribution by a defect in either migration or invasion. 
   To confirm the appearance of aberrant multicentrosomal and multinuclear cells in MDA-MB-
231-shNek2 cultures, we stained the cells with antibodies recognizing α-tubulin, pericentrin or 
centrin2 to visualize microtubules, centrosomes and centrioles, respectively. While most control 
cells displayed two centrosomes and normal mitotic spindles, many MDA-MB-231-shNek2 cells 
showed multiple centrosomes and aberrant mitotic spindles (Figure 5a). An increase in 
centrosome numbers in the absence of Nek2 was confirmed by the quantitation of the number of 
centrioles per pole (Figure 5b). We then evaluated the percentage of cells undergoing monopolar, 
bipolar or multipolar division in control and MDA-MB-231-shNek2 cultures. Nek2 knockdown 
cultures showed a significantly lower percentage of cells with bipolar division, and consequently 
a higher percentage of cells with multipolar division compared to controls (Figure 5c). 
Furthermore, karyotype analysis confirmed a markedly greater number of chromosomes per cell 
in MDA-MB-231-shNek2 cultures compared to controls (Figure 5d, e). 
   To determine the fate of cells lacking Nek2, we used real-time microscopy and MDA-MB-231 
cells engineered to both (1) co-express doxycycline (DOX)-induced shNek2 and red fluorescent 
protein (RFP), and (2) express GFP-conjugated histone 2B (H2B-GFP; to label chromosomes). 
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In the absence of DOX (wild type Nek2 expression), the majority of H2B-GFP-expressing 
MDA-MB-231 cells divided normally into two daughter cells (Figure 5f and Supplementary 
Movie 1). However, when Nek2 knockdown was induced by DOX, the cells exhibited aberrant 
mitosis. Multinuclear cells in these cultures ultimately suffered a mitotic catastrophe and 
underwent apoptosis-like death characterized by extensive membrane blebbing (Figure 5f and 
Supplementary Movie 2). Thus, Nek2 knockdown disrupts the centrosomal machinery, inducing 
aberrant mitosis that produces aneuploid and multinuclear cells and ultimately leads to cell death. 
 
Nek2 knockdown increases caspase-3 cleavage and alters pRb and histone H3 activity 
To verify if the enhanced subG1 population in MDA-MB-231-shNek2 cultures reflected an 
increase in apoptotic cells, we used flow cytometry to evaluate the percentage of cells positive 
for cleaved caspase-3 (CC-3+). After 48 hrs, the percentage of CC-3+ cells in control cultures was 
about 4%, whereas MDA-MB-231-shNek2 cultures displayed 4 times more CC-3+ cells (Figure 
6a, left). The addition of zVAD, a pan-caspase inhibitor, did not change the percentage of CC-3+ 
cells in control cultures but significantly decreased the percentage of CC-3+ cells in MDA-MB-
231-shNek2 cultures (Figure 6a, left). Application of zVAD also decreased the subG1 population 
among MDA-MB-231-shNek2 cells by 20% but had no effect on the subG1 population in the 
control (Figure 6a, right). Increased apoptosis in the absence of Nek2 was also confirmed by 
immunohistochemical analysis of CC-3 in tumors isolated from xenografted NIH-III mice. More 
CC-3+ cells were observed in tumors from animals xenografted with MDA-MB-231-shNek2 
cells compared to tumors from control animals (Figure 6b). At the molecular level, MDA-MB-
231-shNek2 cells revealed reduced phosphorylated pRb and phosphorylated histone H3-Ser10 
compared to controls (Figure 6c). This result is in line with previous observations that 
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hypophosphorylated pRb functions as a tumor suppressor by inhibiting cell cycle progression, 
and that phosphorylated histone H3-Ser10 is required for normal chromosome segregation (24, 
25). The fact that abnormalities in these vital cell cycle factors are observed when Nek2 is 
depleted further substantiates our contention that Nek2 is required for proper cell cycle 
progression and chromosome segregation. 
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Discussion 
Over the past few decades, huge efforts have been undertaken to identify new key players in 
breast cancer progression and metastasis. It is well known that tumor cells act completely 
differently in culture than they do in vivo, where they are surrounded by stromal cells and 
interact with cells of the immune system. These considerations led us to use living animals to test 
a selection of putative therapeutic targets relevant to breast cancer. We have identified several 
kinases and cytoskeletal regulators that, when knocked down, reduce or completely inhibit tumor 
growth in vivo. The particular target examined in this study was Nek2, which is overexpressed in 
cases of all subtypes of breast cancer. Such overexpression is likely due to amplification of 
chromosomal region 1q32, which contains the human Nek2 locus (26). In our study, we have 
confirmed that Nek2 overexpression correlates positively with higher risks of disease recurrence 
and mortality in breast cancer patients. We have also shown that Nek2-depleted human breast 
cancer cells grow poorly in the lungs and mammary fat pads of xenografted mouse recipients. 
Others have previously reported that Nek2 has a pivotal role in tumor cell growth and apoptosis 
(23, 27), we propose that the main effects of Nek2 depletion are a block in cell cycle progression 
and interference with chromosomal segregation, leading to aneuploidy and subsequent cell death. 
   We observed that human breast cancer cells lacking Nek2 proliferated less than control cells 
and displayed a higher percentage of cells in the G2/M phase. Moreover, cultures of mouse 
PyMT cells and human TNBC cells both showed a huge population of aneuploid cells and a 
parallel increase in the subG1 population. Aneuploidy and chromosome instability are common 
abnormalities in human cancers and are linked to poor clinical outcome (32). Loss of control 
over mitotic progression, spindle formation, and cytokinesis are all likely to contribute to these 
abnormalities. However, aneuploidy and aberrant mitosis can also precipitate chromosomal 
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breakage or interchromosomal concatenation, resulting in a lethal genetic imbalance that leads to 
cell death. Thus, aneuploidy can be a promoter or suppressor for mutations that inhibit tumor cell 
growth or induce cell death (33). Our data show that Nek2 knockdown cells display multipolar 
centrosomes and aberrant mitotic figures. Nek2 is known to phosphorylate mitotic checkpoint 
proteins such as Mad2 and Cdc20 (34), and to interact with the spindle assembly checkpoint 
protein Mad1 (31). Nek2 also contributes to the microtubule reorganization necessary for the 
G2/M transition by phosphorylating several centrosomal substrates, including c-Nap1, rootletin, 
PP1, Nlp, centrobin and HMGA2 (28, 29). In accordance with these observations, we could 
demonstrate that multinuclear cells that lack Nek2 died during mitosis. We also found a higher 
percentage of CC-3+ cells in tumors of mice injected with Nek2 knockdown cells compared to 
tumors of mice injected with control cells. Taken together, these data suggest that the aneuploidy 
associated with Nek2 depletion can induce cancer cell death. 
   Phosphorylation of histone H3-Ser10 is required for normal chromosome condensation and 
segregation. Our study has shown that Nek2 depletion greatly reduces histone H3-Ser10 
phosphorylation. In vitro, Nek2 can phosphorylate histone H3 either directly or through 
Erk1/p90Rsk2, but it remains under debate if Nek2 can phosphorylate histone H3 in vivo (18, 35, 
36). In addition, although a direct link between Nek2 and pRb regulation has yet to be reported, 
we have demonstrated that Nek2 depletion decreases the level of pRb phosphorylation. This 
reduction could allow more pRb molecules to remain active and inhibit cell cycle progression. 
Alternatively, Nek2 and pRb signaling could be interconnected through the mitotic kinetochore 
protein Hec1. Previous work has shown that Nek2 may participate in chromosome condensation 
through its interactions with Hec1 (30), and Nek2-dependent phosphorylaton of Hec1 is essential 
for kinetochore attachments to microtubules during mitosis (37). Hec1 is functionally linked to 
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the pRb pathway because disruption of pRb activity leads to Hec1 overexpression, inducing 
defects in chromosome segregation and mitosis (38). Collectively, these data suggest that Nek2 
may be involved in regulating both the histone H3 and pRb pathways. 
   Interference with mitosis is a well-recognized modality of anti-cancer therapy. The 
chemotherapeutic drug Taxol triggers cell death by inactivating the spindle checkpoint, thus 
inducing aneuploidy and aberrant mitosis (39). Kinase inhibitors that have the same effects on 
tumor cells might therefore be helpful adjuncts when used in combination with chemotherapeutic 
drugs based on other strategies. Viridin analogs, which are highly specific inhibitors of Nek2, 
can induce centrosome disruption and inhibit cancer cell growth in vitro (40). Other recent work 
has indicated that Nek2 silencing can induce apoptosis of cells that show chromosomal 
instability but not of cells with a normal karyotype (41, 42). Our study provides in vivo 
validation of the concept that Nek2 is important for tumor growth in both primary and secondary 
sites, and strengthens the rationale underlying the growing efforts to develop specific therapeutic 
inhibitors against this kinase. 
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Material and Methods 
 
Cell lines and plasmids 
PyMT mammary tumor cells were derived from MMTV-PyMT mice and maintained as 
previously reported (13). All human breast cancer cell lines (MDA-MB-231, HCC1806, T47D, 
MCF7) were obtained from ATCC. Unless otherwise indicated, all cell lines were maintained in 
complete medium (CM), which was DMEM supplemented with 10% fetal bovine serum (FBS). 
For serum starvation, cells were cultured overnight in serum-free DMEM. For nocodazole 
treatment, cells were cultured overnight in CM containing 100 ng/ml nocodazole (Sigma). For 
stable knockdown, control scramble shRNA and gene-specific shRNAs were purchased for 
lentiviral expression: pLKO.1 for mouse PyMT cells, and pGIPZ/pTRIPZ for human breast 
cancer cells (Sigma, Open Biosystems). 
 
Microarray analysis 
i) Datasets used: We developed a database comprised of 15 publicly available mRNA expression 
datasets (PMIDs: 16273092, 17545524, 16141321, 16280042, 16478745, 18498629, 17157792, 
19421193, 20098429, 20064235, 20490655, 20697068, 18821012, 18593943, 15721472). Raw 
data was pre-processed using the RMA algorithm (12582260) with Entrez Gene annotation 
(PMID: 16284200). Pre-processing was performed in the R statistical environment (v2.11.1) 
using the affy package of BioConductor (v1.26.1) and v12.1.0 of the updated Entrez Gene 
annotation packages. 
ii) Ortholog mapping: Human genes were mapped to their mouse orthologs using the 
Homologene database (build 64) and custom perl scripts. 
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iii) Statistical analysis and data visualization: Signal intensities of each candidate gene were 
median-dichotomized in each dataset, as outlined previously (PMID: 20696928), in the R 
statistical environment (v2.12.1). Survival rates of patients in the “good” and “poor” outcome 
groups were compared using unadjusted Cox proportional hazards modeling, as implemented in 
the survival package (v2.36-5). Gene association with patient prognosis: the Wald test was 
employed to determine if the hazard ratio (HR) was statistically different from unity. Kaplan-
Meier curves were created using the lattice (v0.19-19) and latticeExtra (v0.6-15) packages. 
 
Quantitative real-time PCR 
TRIzol reagent (Invitrogen) was used for total RNA extraction and the iScript reverse 
transcription kit (BioRad) was used to produce cDNA. qRT-PCR reactions were performed in 
triplicate using SYBR Green mix (AppliedBiosystems) and an Applied Biosystems Real-time 
PCR-7900HT instrument. The amplification of the gapdh/GAPDH gene was used as an internal 
reference control. 
 
Cell proliferation 
Cells were cultured for up to 6 days in CM. Cells were stained with trypan blue and analysed 
using a Vi-Cell XR instrument (Beckman Coulter) to determine viability and establish growth 
curves. For real-time cell proliferation, cells were subjected to serum starvation or nocodazole 
treatment as described above, cultured in CM for an additional 5 days, and monitored using an 
xCELLigence RTCA DP device (Roche Diagnostics). The proliferation rate was expressed as the 
slope [1/h], where a higher slope represents faster cell growth. Cell proliferation was also 
analysed by BrdU incorporation and flow cytometry. Briefly, serum-starved or nocodozole-
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treated cells were cultured overnight in CM containing BrdU starting at 24 hrs or 72 hrs after 
CM replenishment. BrdU incorporation was detected using the APC-BrdU kit (BD) following 
the manufacturer’s instructions. 
 
Migration and invasion assays 
Transwell filters coated with collagen-I or Matrigel (BD Biosciences, 8 µm pore size) were used 
for migration or invasion assays, respectively. Cells (2.5x104 for migration assays or 5x104 for 
invasion assays) were seeded into the upper chamber in DMEM with 0.5% FBS. The bottom 
chamber contained DMEM with 20% FBS. Cells were allowed to migrate/invade at 37°C in 5% 
CO2 for 20 hrs before they were fixed and stained in methanol/methylene-blue solution. Cell 
counts were performed on 10 fields per filter, and the mean was normalized to the 
migration/invasion cell count of control cells. Real-time cell migration was evaluated using the 
xCELLigence RTCA DP device (Roche Diagnostics). For this purpose, 1x104, 2x104 or 4x104 
MDA-MB-231 cells per well were seeded in CIM-Plates 16 (Roche Diagnostics). The migration 
rate was expressed as the slope [1/h], where a higher slope represents faster cell movement. 
 
Cell cycle analysis 
Cells (2x105) were cultured overnight in serum-free medium or in CM containing nocodazole 
(100 ng/ml). The medium was changed to CM and the cells were cultured for 24, 48, 72, 96 or 
120 hrs. After ethanol fixation, cells were washed with PBS, suspended in PBS containing 2 
µg/ml propidium iodide (Sigma) plus 20 mg/ml RNAse (Invitrogen), and examined using a 
FACSCalibur instrument and ModFit software (BD Biosciences). To evaluate CC-3+ cells by 
flow cytometry, the PE Active Caspase-3 Apoptosis Kit (BD Biosciences) was used following 
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the manufacturer’s instructions. Cells were acquired and analysed with CellQuest software (BD 
Biosciences). For caspase inhibitor studies, cells were cultured in CM containing 50 µM zVAD 
(Sigma) for 48 hrs prior to cell cycle analysis as described above. CC-3+ cells without zVAD 
were evaluated in a parallel set of plates as a control. 
 
In vivo analyses of tumor growth 
Luciferase-expressing MDA-MB-231 or PyMT cells (2.5x105 in 200µl PBS) co-expressing 
scramble or gene-specific shRNAs were injected into the tail vein of 8-week-old NOD-SCID or 
129P2Ola female recipients, respectively. Imaging of luciferase-expressing tumor cells was 
performed using the Xenogen system (IVIS, Caliper Life Sciences). Mouse survival was 
evaluated using Kaplan-Meier methodology. For in vivo tumor growth analysis, control MDA-
MB-231 or MDA-MB-231-shNek2 cells were injected into the fat pads (1x106 cells in Matrigel) 
of 8-week-old NIH-III nu/nu mice, or into the tail vein (2.5x105 cells in 200µl PBS) of NOD-
SCID female mice. After 35 days, recipient mice were sacrificed and tumors and lungs were 
excised. Tumor weights were recorded and tissues processed for further analysis. All animal 
experiments were approved by the Animal Care and Use Committee of the University Health 
Network (Toronto, Canada). 
 
Karyotyping 
Cells were cultured in CM containing nocodazole (100 ng/ml) for 5 hrs before treatment with 
hypotonic solution (0.56% KCl) and fixation in methanol/acetic acid (3:1). Metaphase 
chromosome spreads were prepared on glass microscope slides, stained with Giemsa solution 
21 
(Sigma), and counted/analysed using an upright light microscope (Leica DM2500) equipped with 
a 40x air-lens. 
 
Immunofluorescence and real-time microscopy 
For immunofluorescence, MDA-MB-231 cells (1x104) were seeded in 8-well chamber slides 
(Lab-Tek, Nunc) and cultured overnight in serum-free medium or CM containing nocodazole 
(100 ng/ml). The medium was changed to CM and cells were cultured for a further 48 hrs before 
paraformaldehyde fixation, Triton X-100 permeabilization, and blocking in goat serum 
containing BSA. Slides were then incubated with primary anti-α-tubulin (Sigma-Aldrich), anti-
pericentrin (Abcam), or anti-centrin2 (Santa Cruz) antibodies, followed by species-specific 
fluorescent secondary antibodies (Molecular Probes). DNA was detected with 1.5 µg/ml 4,6-
diamidino-2-phenylindole (VECTASHIELD Mounting Medium with DAPI; Vector 
Laboratories). Fluorescent images were obtained and processed using an Olympus-Fluoview-
FV1000 confocal microscope. 
   For real-time microscopy, MDA-MB-231 cells co-expressing doxycycline-inducible red 
fluorescent protein (RFP) and shNek2 were transfected with pBOS human histone 2B-GFP 
plasmid using Lipofectamine2000 (Invitrogen). Transfected cells (1x104) were seeded in 8-well 
chamber slides and cultured overnight as above. The medium was changed to CM with or 
without doxycycline (500 ng/ml), and cells were cultured and recorded for an additional 150 hrs 
at 37°C in 5% CO2. The CM with or without doxycycline was replaced every 48 hrs. Cells were 
recorded using a Leica DMI 6000B instrument and image analysis was performed using Volocity 
software. 
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Immunohistochemistry (IHC) 
Tissues were fixed in 10% buffered formalin and embedded in paraffin. Tissue sections (5µm) 
were stained with hematoxylin and eosin, or subjected to immunohistochemical staining to detect 
CC-3. Briefly, tissue sections were incubated first with anti-CC-3 antibody (1:250; Cell 
Signaling), then with biotinylated goat anti-rabbit secondary antibody (1:100, Vector Labs), and 
exposed to ABC reagent (1:200 final A and B dilution; PK-6100, Vector Labs). The DAB 
substrate kit (SK-4100, Vector Labs) was used to visualize anti-CC-3 antibody staining. Imaging 
was performed on a Leica DM2500 microscope. 
...The tissue microarray contains 39 triple negative breast cancers from our institution. For each 
case there were two 0.6 mm biopsy-cores of invasive carcinoma and one of normal breast tissue 
taken. Invasive carcinoma cells (IDCs) were scored for percentage of cells showing nuclear 
Nek2 expression. The degree of Nek2 expression intensity was also scored (S=strong, 
I=intermediate, W=weak). Tissue microarray was microwaved, exposed to Tris-EDTA pH 9.0 
and incubated with anti-Nek2 antibody (1:100, BD) over night. The BioGenx polymer kit was 
used for detection. 
 
Immunoblotting 
Cell extracts were prepared in RIPA buffer. Equal amounts of protein were resolved by SDS-
PAGE and subjected to standard immunoblotting using antibodies recognizing phospho-Rb, total 
Rb, phospho-histone H3-Ser10 (all from Cell Signaling); total histone H3 (Abcam); or G6PDH 
(Sigma). 
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Statistics 
Kaplan-Meier survival plots and intergroup comparison statistics were determined using 
GraphPad PRISM-5 software. The log-rank test was used to evaluate differences in animal 
survival among experimental groups (p value). The two-tailed Student’s t-test with standard error 
of the mean (SEM) was used to evaluate differences in all other assays. 
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Figure Legends 
 
Figure 1. Target selection for in vivo tumor growth study and characterization of Nek2 in human 
breast cancers. 
(a) Selected human genes associated with poor breast cancer patient prognosis. The human gene 
ID number and target name are indicated, as well as each target’s hazard ratio (HR) related to 
overall patient survival, the p value, and the number (n) of breast cancer patients analyzed for 
that target. (b) Relative Nek2 mRNA expression (density) in normal breast tissue, basal-like or 
non-basal-like breast cancer tissues, extrapolated from the Richardson data set (20). (c) Survival 
curve for a cohort of 2312 breast cancer patients stratified based on high or low Nek2 expression 
in the patient’s tumor. The HR and p values for the correlation between Nek2 level and patient 
prognosis are indicated. (d) Relapse-free survival curves (RFS) of patients bearing breast cancers 
of the basal, luminal A or luminal B subtypes, stratified based on high or low Nek2 expression in 
the patient’s tumor (22). The HR and p values for the correlation between Nek2 level and patient 
prognosis are indicated. (e) IHC, NEK2 protein expression in triple-negative breast cancers 
(TNBC) from a cohort of 39 patients. 3 representative examples of NEK2 expression in TNBCs 
(1% positive nuclei – W=weak intensity; 20% positive nuclei – S=strong intensity; 80% positive 
nuclei – S=strong intensity) are shown in comparison to normal breast tissue (zero intensity). (f) 
NEK2 positive nuclei per biopsy-core. Mean percentage ± SEM. (g) Percentage of biopsy-cores 
(total 39 TNBCs and 39 corresponding controls of normal breast tissue, see Supplementary Table 
S1) that show S=strong, I=intermediate, W=weak and zero staining intensity. 
 
Figure 2. Nek2 promotes mouse tumor cell growth in vivo. 
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(a) qRT-PCR analysis of Nek2 mRNA expression in mouse PyMT cells transduced with 
lentiviral vectors expressing control scramble shRNA (ctr) or shNek2 #1 or #2. Data were 
normalized to Gapdh mRNA and expressed relative to levels in control cells (set to 1.0). Results 
are the mean ± SEM of triplicates. (b) Immunoblot of Nek2 protein in the PyMT-ctr and PyMT-
shNek2 cells in (a). G6PDH, loading control. (c) Time course of the in vivo growth of PyMT-ctr 
and PyMT-shNek2 cells injected into the tail veins of female 129P2Ola mice. Mice were 
subjected to whole animal imaging using an IVIS Spectrum Imaging system at the indicated 
timepoints post-injection. Scaling intensity of images was normalized to control. One group of 5 
animals per experimental condition is shown. (d) Kaplan-Meier survival curve of the mice in (c) 
(n=5/group). (e) Flow cytometric cell cycle analysis of serum-starved PyMT-ctr and PyMT-
shNek2 cells at the indicated timepoints after serum replenishment. Red peaks, G1 and G2/M 
phases of diploid cells; blue peak, subG1 phase (dead cells); yellow peaks, G1 and G2/M phases 
of aneuploid cells. Results are representative of three independent experiments. (f) Quantitation 
of the cell cycle analyses in (e). (g) Quantitation of the percentages of the cells in (e) that were 
diploid (DIP) or aneuploid (ANE). For (e), (f) and (g), representative results are shown out of 
triplicates. 
 
Figure 3. Lack of Nek2 reduces the growth of MDA-MB-231 cells in vivo. 
(a) qRT-PCR analysis of Nek2 mRNA expression in human MDA-MB-231 cells transduced with 
lentiviral vectors expressing control scramble shRNA (ctr) or shNek2 #3 or #10. Data were 
analyzed relative to GAPDH mRNA levels as in Figure 2a. Results are the mean ± SEM of 
triplicates. (b) Immunoblot of Nek2 protein in the MDA-MB-231-ctr and MDA-MB-231-shNek2 
#3 or #10 cells in (a) analyzed as in Figure 2b. (c) Time course of the in vivo growth of MDA-
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MB-231-ctr and MDA-MB-231-shNek2#3 cells injected into the tail veins of NOD-SCID mice. 
Mice were subjected to whole animal imaging and analyzed as in Figure 2c. (d) Kaplan-Meier 
survival curve of the mice in (c). (e) Weights of tumors excised from NIH-III nu/nu mice whose 
fat pads were injected with MDA-MB-231-ctr or MDA-MB-231-shNek2#3 cells. Data are the 
mean of 5 tumors per group ± SEM. Inset: GFP-positive MDA-MB-231-shNek2#3 cells are 
clearly evident in the fat pads of all injected mice, confirming the expression of the shNek2 
lentiviral vector. (f) Left panel: Quantitation of the ratio of ‘tumor tissue area/lung tissue area’ in 
mice IV-injected with MDA-MB-231-ctr or MDA-MB-231-shNek2#3 cells at 35 days post-
injection. Data are the mean of 3 sections per 2 lungs per group ± SEM. Right panel: 
Representative H&E-stained sections of lungs from the IV-injected mice in the left panel. 
 
Figure 4. Nek2 knockdown induces cell growth arrest, aneuploidy and aberrant mitosis. 
(a) Flow cytometric cell cycle analysis of MDA-MB-231-ctr and MDA-MB-231-shNek2 #3 and 
#10 cells at the indicated timepoints after serum starvation. Data were analyzed as in Figure 2e. 
(b) Quantitation of the cell cycle analyses in (a). (c) Quantitation of percentages of the cells in (a) 
that were diploid (DIP) or aneuploid (ANE). (d) Evaluation of the real-time proliferation of 
MDA-MB-231-ctr and MDA-MB-231-shNek2#3 cells using an xCELLigence RTCA DP 
instrument. Data are expressed as the slope [1/h], where a higher slope represents faster cell 
growth. (e) Quantitation of the percentage of BrdU+ cells (replicating cells) of MDA-MB-231-ctr 
and MDA-MB-231-shNek2#3 cultures at the indicated times after serum starvation. (f) 
Quantitation of the percentage of BrdU+ cells in MDA-MB-231-ctr and MDA-MB-231-
shNek2#3 cultures at the indicated times after nocodazole treatment. For (a), (b) and (c) results 
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are representative of three independent experiments. For (d), (e) and (f), results are the mean ± 
SEM of triplicates. 
 
Figure 5. Nek2 knockdown increases centriole numbers, causes multinucleation, and 
aneuploidy. 
(a) Immunofluorescent analysis of centrosomes (red) and microtubules (green in MDA-MB-231-
ctr cells, and red in GFP-expressing MDA-MB-231-shNek2 cells) in dividing control and Nek2 
knockdown cells at 48 hrs after nocodazole treatment. Smaller panels on the right are higher 
magnification images of representative cells in the left panels. Results are representative of two 
independent experiments. (b) Quantitation of the numbers of centrioles per pole in the MDA-
MB-231-ctr and MDA-MB-231-shNek2#3 in (a) (n=60/group) determined by staining with anti-
centrin2 antibody. (c) Quantitation of the bipolar, multipolar and monopolar divisions of the cells 
in (a) (n=60 cells/group) determined by staining with anti-α-tubulin antibody. (d) Metaphase 
chromosome spreads of MDA-MB-231-ctr and MDA-MB-231-shNek2 cells vizualized by 
Giemsa staining. Images are representative of 35 cells/group examined. (e) Quantitation of total 
chromosome numbers in the MDA-MB-231-ctr and MDA-MB-231-shNek2 cells in (d). (f) 
Snapshots from real-time microscopy generating Supplementary Movies 1 and 2. The mitosis of 
MDA-MB-231 cells expressing doxycycline (DOX)-inducible shNek2 and RFP (red), along with 
H2B-GFP (green), was followed. Multinucleated cells can be seen in images of DOX-treated 
(Nek2 knockdown) cells. The “Merge” column contains overlaid images of the red, green and 
bright fields. For (b), (c) and (e), results are the mean ± SEM. 
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Figure 6. Nek2 knockdown increases cleaved caspase-3 and alters pRB and histone H3 
phosphorylation. 
(a) Quantitation of CC-3+ cells and subG1 cells (dead cells) in cultures of MDA-MB-231-ctr and 
MDA-MB-231-shNek2#3 cells that were serum-starved overnight and cultured for 48 hrs in CM 
plus DMSO alone (vehicle) or DMSO containing zVAD, as indicated. Percentages of CC-3+ 
(left) and subG1 (right) cells were determined by flow cytometry. Data are the mean ± SEM and 
are representative of two independent experiments. (b) Immunohistochemical analysis of CC-3+ 
cells in tumors of NIH-III mice whose fat pads were injected with MDA-MB-231-ctr or MDA-
MB-231-shNek2#3 cells. Results are representative of 5 tumors/group examined. (c) 
Immunoblot to detect the indicated proteins in extracts of MDA-MB-231-ctr (-) and MDA-MB-
231-shNek2#3 (+) cells at the indicated timepoints after release from nocodazole (NOC) 
treatment. G6PDH, loading control. 
